Faculty

Institution

Unit

Venue

Hui Lyu

Louisiana State University Health Sciences Center, New Orleans

Affiliations

School of Medicine

Department Of Interdisciplinary Oncology

Departments Of Microbiology And Immunology, Genetics And Medicine

Louisiana State University Health Sciences Center, New Orleans

NoneHui Lyu is currently serving as a Interdisciplinary Oncology faculty at Louisiana State University Health Sciences Center, New Orleans.

Honors

Create free account to unlock more features

Experiences

Create free account to unlock more features

Education

Create free account to unlock more features

Hui Lyu

Louisiana State University Health Sciences Center, New Orleans

You can click a keyword to filter the displayed items

cell biology cancer cells breast cancer oncogenes cancer biology tumor biology therapeutic targets molecular cancer breast oncology pharmacology anti-cancer agents cancer research medicinal research oncology molecular cell biology cancer treatment tumor targeting cancer growth radiation oncology cancer genetics immunology microrna detection antitumor activity cancer immunotherapy lung cancer cancer discovery drug targeting oncogenic agent receptor tyrosine kinases pharmacotherapy thoracic oncology cell death cellular therapy signaling pathways cancer genomics hematological malignancies multiple myeloma cells receptors cancer imaging cancer care small rna tumor suppressors cell regulation apoptosis enzyme inhibition scientific data ethnic studies leukemia drug targets rna biology receptor (biochemistry) cell proliferation novel therapies health disparities health care disparities cancer disparities extracellular microvesicles mesenchymal stem cells myeloid neoplasia clinical radiation oncology cancer prevention cancer registration human cancer alkbh5-mediated m6a demethylation her2-targeted therapy her2-positive breast cancer confers herceptin resistance foxo3a-mirna feedback inhibition microrna regulation anti-erbb3 antibody mm-121/sar256212 therapeutic targeting erbb2-overexpressing breast cancer her2-overexpressing breast cancer cancer therapeutic resistance epigenetic mechanism dna damage response

Notable Scholarly Works

Notable Federal Grants

Collaborators

Abstract 4049: Transcriptional Regulation of Foxa1 by Gata2/3 Attenuates the Antitumor Effects of Histone Deacetylase (Hdac) Inhibitors in Basal-Like Breast Cancer. Cancer Research (2025)

gene expressioncancer geneticscancer researchmolecular cancerabstract 4049transcription factorsmolecular cell biologybreast cancermolecular biologyhistone deacetylasecancer cellsepigeneticscancer biologytumor biologytranscriptional regulationcell biology

Abstract A058: Investigating Metformin as a Unique Therapeutic for Kras-Mutant Non-Small Cell Lung Cancer. Molecular Cancer Therapeutics (2025)

bronchial neoplasmpharmacologycancer biologythoracic oncologytherapeutic targetscancer growthanti-cancer agentsabstract a058molecular biologyoncogenic agentoncogenescancer cellstumor microenvironmentlung cancertumor biologycell biology

Her3 Promotes Triple-Negative Breast Cancer Progression by Upregulating Phf8 via Mir-34B-5P-Dependent Mechanism. Cell Death and Disease (2025)

systems biologytranscription factorsmolecular cell biologycancer growthbreast oncologybreast canceroncogenescancer cellscancer biologytumor biologymir-34b-5p-dependent mechanismcell biology

Phgdh Activity in Triple-Negative Breast Cancer Studies--a Glimmer of Hope in the Midst of Difficult Treatment Process. medRxiv (2025)

phgdh activityendocrine-related cancersradiation oncologycancer discoverytherapeutic targetsdifficult treatment processbreast oncologyoncologybreast cancercancer cellscell biology

Subtype-Specific Her3 Enrichment in Basal-Like Breast Cancer is Regulated via the Gata2/Gata3–Foxa1 Axis. Cancer Letters (2025)

cancer geneticscancer researchmolecular cancertranscription factorscancer genomicsmolecular cell biologybreast oncologybreast canceroncogenescancer cellsdevelopmental biologysubtype-specific her3 enrichmentcancer biologybasal-like breast cancertumor biologygata2/gata3–foxa1 axiscell biology

Subtype-Specific Her3 Enrichment in Basal-Like Breast Cancer is Selectively Suppressed by Hdac Inhibitors via the Gata2/Gata3–Foxa1 Axis. SSRN Electronic Journal (2025)

cancer geneticsmolecular cancermolecular cell biologybreast oncologybreast cancermolecular biologyoncogenescancer cellsbasal-like breast cancersubtype-specific her3 enrichmentcancer biologytumor biologygata2/gata3–foxa1 axiscell biology

Synergistic Anti-Tumor Activity of Ciclopirox Olamine and Metformin in Triple-Negative Breast Cancer. Genes & Diseases (2025)

synergistic anti-tumor activitytriple-negative breast cancerendocrine-related cancerspharmacologyfuture medicinal chemistrymolecular cancerciclopirox olaminetherapeutic targetsbreast oncologyanti-cancer agentsdrug discoverybreast cancercancer cellscancer biologycell biology

Abstract 203: Promotion of Metastasis of Erbb2-Positive Breast Cancer by Mesenchymal Stem Cells via Exosomes-Mediated Activation of Erbb2/Erbb3→Pi3K/Akt Singaling Pathway. Cancer Research (2024)

extracellular microvesiclesmetastasisabstract 203systems biologymesenchymal stem cellscellular therapybreast oncologycancer growthstem cellsbreast canceroncogenescancer cellstumor microenvironmenterbb2-positive breast cancercancer biologytumor biologycell biology

Abstract 4549: Combinations of Ciclopirox Olamine and Metformin Exert Synergistic Antitumor Activity in Triple-Negative Breast Cancer. Cancer Research (2024)

triple-negative breast cancerendocrine-related cancerspharmacologycancer researchciclopirox olaminecancer discoverytherapeutic targetsbreast oncologyanti-cancer agentsdrug discoverybreast canceroncologyoncogenescancer cellscancer treatmentabstract 4549cell biology

Abstract 5868: Upregulation of Her3 and Met in Non-Small Cell Lung Cancer Cells Resistant to Egfr Tyrosine Kinase Inhibitor. Cancer Research (2024)

pharmacologycancer biologyreceptor tyrosine kinasesoncogenic agentoncogenescancer cellslung cancerabstract 5868tumor biologycell biology

1
2
3
4
5
6
10 / page

Hui Lyu

Louisiana State University Health Sciences Center, New Orleans

Affiliations

School of Medicine

Department Of Interdisciplinary Oncology

Departments Of Microbiology And Immunology, Genetics And Medicine

Louisiana State University Health Sciences Center, New Orleans

NoneHui Lyu is currently serving as a Interdisciplinary Oncology faculty at Louisiana State University Health Sciences Center, New Orleans.

Honors

Create free account to unlock more features

Experiences

Create free account to unlock more features

Education

Create free account to unlock more features

Hui Lyu

Louisiana State University Health Sciences Center, New Orleans

You can click a keyword to filter the displayed items

Notable Scholarly Works

Notable Federal Grants

Collaborators

Abstract 4049: Transcriptional Regulation of Foxa1 by Gata2/3 Attenuates the Antitumor Effects of Histone Deacetylase (Hdac) Inhibitors in Basal-Like Breast Cancer. Cancer Research (2025)

Abstract A058: Investigating Metformin as a Unique Therapeutic for Kras-Mutant Non-Small Cell Lung Cancer. Molecular Cancer Therapeutics (2025)

Her3 Promotes Triple-Negative Breast Cancer Progression by Upregulating Phf8 via Mir-34B-5P-Dependent Mechanism. Cell Death and Disease (2025)

systems biologytranscription factorsmolecular cell biologycancer growthbreast oncologybreast canceroncogenescancer cellscancer biologytumor biologymir-34b-5p-dependent mechanismcell biology

Phgdh Activity in Triple-Negative Breast Cancer Studies--a Glimmer of Hope in the Midst of Difficult Treatment Process. medRxiv (2025)

phgdh activityendocrine-related cancersradiation oncologycancer discoverytherapeutic targetsdifficult treatment processbreast oncologyoncologybreast cancercancer cellscell biology

Subtype-Specific Her3 Enrichment in Basal-Like Breast Cancer is Regulated via the Gata2/Gata3–Foxa1 Axis. Cancer Letters (2025)

Subtype-Specific Her3 Enrichment in Basal-Like Breast Cancer is Selectively Suppressed by Hdac Inhibitors via the Gata2/Gata3–Foxa1 Axis. SSRN Electronic Journal (2025)

Synergistic Anti-Tumor Activity of Ciclopirox Olamine and Metformin in Triple-Negative Breast Cancer. Genes & Diseases (2025)

Abstract 203: Promotion of Metastasis of Erbb2-Positive Breast Cancer by Mesenchymal Stem Cells via Exosomes-Mediated Activation of Erbb2/Erbb3→Pi3K/Akt Singaling Pathway. Cancer Research (2024)

Abstract 4549: Combinations of Ciclopirox Olamine and Metformin Exert Synergistic Antitumor Activity in Triple-Negative Breast Cancer. Cancer Research (2024)

Abstract 5868: Upregulation of Her3 and Met in Non-Small Cell Lung Cancer Cells Resistant to Egfr Tyrosine Kinase Inhibitor. Cancer Research (2024)

pharmacologycancer biologyreceptor tyrosine kinasesoncogenic agentoncogenescancer cellslung cancerabstract 5868tumor biologycell biology

1
2
3
4
5
6
10 / page